Spots Global Cancer Trial Database for adult primary hepatocellular carcinoma
Every month we try and update this database with for adult primary hepatocellular carcinoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Iodine I 131 Ethiodized Oil in Preventing Recurrent Cancer in Patients Who Have Undergone Treatment for Liver Cancer | NCT00870558 | Liver Cancer | ethiodized oil iodine I 131 et... | 18 Years - | National Cancer Institute (NCI) | |
| Sorafenib Tosylate Before and After Hepatic Arterial Chemoembolization With Doxorubicin Hydrochloride and Mitomycin C in Treating Patients With Localized Liver Cancer That Cannot Be Removed by Surgery | NCT00949182 | Liver Cancer | sorafenib tosyl... laboratory biom... | 18 Years - | Rutgers, The State University of New Jersey | |
| Sorafenib Tosylate With or Without Stereotactic Body Radiation Therapy in Treating Patients With Liver Cancer | NCT01730937 | Adult Primary H... Advanced Adult ... Recurrent Adult... | Sorafenib stereotactic bo... | 18 Years - | Radiation Therapy Oncology Group | |
| Megestrol in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery | NCT00041275 | Liver Cancer | megestrol aceta... | 20 Years - | National Cancer Institute (NCI) | |
| T900607 in Treating Patients With Unresectable Liver Cancer | NCT00054262 | Liver Cancer | T900607 | 18 Years - | National Cancer Institute (NCI) | |
| BMS-247550 in Treating Patients With Liver or Gallbladder Cancer | NCT00023946 | Adult Primary C... Adult Primary H... Advanced Adult ... Cholangiocarcin... Cholangiocarcin... Localized Extra... Localized Gallb... Localized Resec... Localized Unres... Recurrent Adult... Recurrent Extra... Recurrent Gallb... Unresectable Ex... Unresectable Ga... | ixabepilone laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| TAC-101 in Treating Patients With Advanced Hepatocellular Carcinoma (Liver Cancer) | NCT00077142 | Liver Cancer | TAC-101 | 18 Years - 80 Years | M.D. Anderson Cancer Center | |
| Thalidomide Plus Interferon Alfa in Treating Patients With Progressive Liver Cancer That Cannot be Surgically Removed | NCT00006006 | Liver Cancer | recombinant int... thalidomide | 18 Years - | National Cancer Institute (NCI) | |
| Celecoxib and Erlotinib in Treating Patients With Liver Cancer | NCT00293436 | Liver Cancer | celecoxib erlotinib hydro... adjuvant therap... | 18 Years - | University of California, San Francisco | |
| Positron Emission Tomography Using Carbon-11 Acetate and Fludeoxyglucose F 18 in Detecting Hepatocellular Carcinoma (Liver Cancer) in Patients With Known or Suspected Liver Cancer | NCT00081094 | Liver Cancer | 18F-Fluorodeoxy... 11Carbon-Acetat... | 18 Years - | Washington University School of Medicine | |
| Lapatinib Ditosylate in Treating Patients With Unresectable Liver or Biliary Tract Cancer | NCT00107536 | Adult Primary H... Advanced Adult ... Localized Unres... Recurrent Adult... Recurrent Extra... Recurrent Gallb... Unresectable Ex... Unresectable Ga... | lapatinib ditos... laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Panobinostat and Sorafenib in Treating Patients With Liver Cancer That is Metastatic and/or Cannot Be Removed by Surgery | NCT00873002 | Liver Cancer | panobinostat sorafenib tosyl... | 18 Years - | Case Comprehensive Cancer Center | |
| PET-CT in Determining the Radioembolization Dose Delivered to Patients With Liver Metastasis, Primary Liver Cancer, or Biliary Cancer | NCT02088775 | Adult Primary H... Advanced Adult ... Metastatic Extr... Recurrent Adult... Recurrent Extra... Stage D Adult P... Unspecified Adu... | PET scan CT Scan hepatic artery ... | 18 Years - | Fox Chase Cancer Center | |
| Radiation Therapy in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery | NCT00777894 | Liver Cancer | 3-dimensional c... intensity-modul... stereotactic bo... | 18 Years - | Swiss Group for Clinical Cancer Research | |
| Radiolabeled Glass Beads (TheraSphere®) in Treating Patients With Primary Liver Cancer That Cannot Be Removed by Surgery | NCT00039078 | Liver Cancer | yttrium Y 90 gl... | 18 Years - 120 Years | University of Pittsburgh | |
| Transarterial Chemoembolization With Doxorubicin With or Without Everolimus in Treating Patients With Liver Cancer | NCT01009801 | Liver Cancer | doxorubicin-elu... everolimus placebo | 18 Years - | Swiss Group for Clinical Cancer Research | |
| Radiolabeled Glass Beads in Treating Patients With Liver Cancer That Cannot be Removed by Surgery | NCT02072356 | Adult Primary H... Advanced Adult ... Localized Unres... Recurrent Adult... | yttrium Y 90 gl... laboratory biom... TheraSphere | 8 Years - | Ohio State University Comprehensive Cancer Center | |
| Celecoxib and Erlotinib in Treating Patients With Liver Cancer | NCT00293436 | Liver Cancer | celecoxib erlotinib hydro... adjuvant therap... | 18 Years - | University of California, San Francisco | |
| A Treatment of Unresectable Hepatocellular Carcinoma With TheraSphere® | NCT00877136 | Liver Tumors Hepatocellular ... Hepatoma Neoplasms | TheraSphere® | 18 Years - | St. Joseph Hospital of Orange | |
| Sunitinib in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery | NCT00514228 | Liver Cancer | sunitinib malat... | 18 Years - | Swiss Group for Clinical Cancer Research | |
| Selumetinib in Treating Patients With Locally Advanced or Metastatic Liver Cancer | NCT00604721 | Adult Primary H... Advanced Adult ... Localized Unres... Recurrent Adult... | selumetinib pharmacological... | 18 Years - | National Cancer Institute (NCI) | |
| Chinese Herbal Formulation PHY906 and Sorafenib Tosylate in Treating Patients With Advanced Liver Cancer | NCT01666756 | Adult Primary H... Advanced Adult ... Advanced Adult ... BCLC Stage B Ad... BCLC Stage C Ad... | Chinese herbal ... sorafenib tosyl... laboratory biom... pharmacological... | 18 Years - | City of Hope Medical Center | |
| Bevacizumab and Chemoembolization in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery | NCT00335829 | Liver Cancer | bevacizumab chemotherapy embolization th... hepatic artery ... | 18 Years - 120 Years | Yale University | |
| Bevacizumab and Chemoembolization in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery | NCT00335829 | Liver Cancer | bevacizumab chemotherapy embolization th... hepatic artery ... | 18 Years - 120 Years | Yale University | |
| Stereotactic Body Radiation Therapy in Liver Cancer That Cannot be Removed by Surgery or Transplant | NCT01194206 | Adult Primary H... Advanced Adult ... Localized Unres... Recurrent Adult... | stereotactic bo... | 18 Years - 70 Years | Case Comprehensive Cancer Center | |
| Radiolabeled Glass Beads in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery | NCT00530010 | Liver Cancer | yttrium Y 90 gl... | 18 Years - | Northwestern University | |
| Epirubicin and Celecoxib in Treating Patients With Hepatocellular Carcinoma | NCT00057980 | Liver Cancer | celecoxib epirubicin hydr... | 18 Years - | Northwestern University | |
| Epirubicin and Celecoxib in Treating Patients With Hepatocellular Carcinoma | NCT00057980 | Liver Cancer | celecoxib epirubicin hydr... | 18 Years - | Northwestern University | |
| T900607 in Treating Patients With Unresectable Liver Cancer | NCT00054262 | Liver Cancer | T900607 | 18 Years - | National Cancer Institute (NCI) | |
| Quality of Life in Patients Undergoing Embolization Using Yttrium Y 90 Glass Microspheres for Primary or Metastatic Liver Cancer | NCT00739167 | Liver Cancer Metastatic Canc... | 18 Years - | Northwestern University | ||
| Cisplatin or Carboplatin and Sorafenib in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery | NCT00875615 | Liver Cancer | Carboplatin Cisplatin Sorafenib | 18 Years - 120 Years | University of Miami | |
| YIV-906 (Formerly PHY906/KD018) With Sorafenib in HBV(+) Hepatocellular Carcinoma (HCC) | NCT04000737 | Advanced Hepato... | YIV-906+Sorafen... Placebo+Sorafen... | 18 Years - | Yiviva Inc. | |
| Stereotactic Radiation Therapy in Treating Patients With Advanced Liver Cancer | NCT00607828 | Liver Cancer | stereotactic bo... | 19 Years - 120 Years | University of Nebraska | |
| Temsirolimus in Treating Patients With Advanced Liver Cancer and Cirrhosis | NCT01079767 | Liver Cancer | temsirolimus | 18 Years - | Federation Francophone de Cancerologie Digestive | |
| IMC-A12 in Treating Patients With Advanced Liver Cancer | NCT00639509 | Adult Primary H... Advanced Adult ... Localized Unres... Recurrent Adult... | cixutumumab computed tomogr... contrast-enhanc... | 18 Years - | National Cancer Institute (NCI) | |
| Bevacizumab and Erlotinib or Sorafenib as First-Line Therapy in Treating Patients With Advanced Liver Cancer | NCT00881751 | Liver Cancer | bevacizumab erlotinib hydro... sorafenib tosyl... | 18 Years - 116 Years | Medical University of South Carolina | |
| A Treatment of Unresectable Hepatocellular Carcinoma With TheraSphere® | NCT00877136 | Liver Tumors Hepatocellular ... Hepatoma Neoplasms | TheraSphere® | 18 Years - | St. Joseph Hospital of Orange | |
| Tumor Necrosis Factor in Patients Undergoing Surgery for Primary Cancer or Metastatic Cancer | NCT00436410 | Adrenocortical ... Breast Cancer Colorectal Canc... Gastrointestina... Kidney Cancer Liver Cancer Melanoma (Skin) Ovarian Cancer Pancreatic Canc... Sarcoma | colloidal gold-... electron micros... pharmacological... conventional su... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Lapatinib in Treating Patients With Locally Advanced or Metastatic Biliary Tract or Liver Cancer That Cannot Be Removed By Surgery | NCT00101036 | Adult Primary H... Advanced Adult ... Localized Unres... Recurrent Adult... Recurrent Extra... Recurrent Gallb... Unresectable Ex... Unresectable Ga... | lapatinib ditos... laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Sorafenib Tosylate Following a Liver Transplant in Treating Patients With Liver Cancer | NCT01624285 | Adult Primary H... Localized Resec... Localized Unres... Recurrent Adult... | sorafenib tosyl... placebo laboratory biom... | 19 Years - | Jonsson Comprehensive Cancer Center | |
| Gefitinib in Treating Patients With Advanced Unresectable Hepatocellular Carcinoma (Liver Cancer) | NCT00071994 | Adult Primary H... Advanced Adult ... Localized Unres... Recurrent Adult... | gefitinib laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Erlotinib in Treating Patients With Unresectable Liver Cancer and Liver Dysfunction | NCT00047346 | Adult Primary H... Advanced Adult ... Localized Unres... Recurrent Adult... | erlotinib hydro... pharmacological... laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Vaccine Therapy in Treating Patients With Advanced or Metastatic Cancer | NCT00027534 | Breast Cancer Colorectal Canc... Gallbladder Can... Gastric Cancer Head and Neck C... Liver Cancer Ovarian Cancer Pancreatic Canc... Testicular Germ... | TRICOM-CEA(6D) | 18 Years - | Duke University | |
| BMS-247550 in Treating Patients With Liver or Gallbladder Cancer | NCT00023946 | Adult Primary C... Adult Primary H... Advanced Adult ... Cholangiocarcin... Cholangiocarcin... Localized Extra... Localized Gallb... Localized Resec... Localized Unres... Recurrent Adult... Recurrent Extra... Recurrent Gallb... Unresectable Ex... Unresectable Ga... | ixabepilone laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Radioactive Iodine in Treating Patients Who Have Undergone Surgery for Liver Cancer | NCT00027768 | Liver Cancer | adjuvant therap... iodine I 131 et... | 17 Years - | National Cancer Institute (NCI) | |
| Bevacizumab and Chemoembolization in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery | NCT00335829 | Liver Cancer | bevacizumab chemotherapy embolization th... hepatic artery ... | 18 Years - 120 Years | Yale University | |
| Thalidomide and Chemoembolization With Doxorubicin in Treating Patients With Liver Cancer That Cannot be Removed by Surgery | NCT00006016 | Adult Primary H... Advanced Adult ... Localized Unres... | thalidomide doxorubicin hyd... laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Thalidomide Plus Interferon Alfa in Treating Patients With Progressive Liver Cancer That Cannot be Surgically Removed | NCT00006006 | Liver Cancer | recombinant int... thalidomide | 18 Years - | National Cancer Institute (NCI) | |
| Quality of Life in Patients Undergoing Embolization Using Yttrium Y 90 Glass Microspheres for Primary or Metastatic Liver Cancer | NCT00739167 | Liver Cancer Metastatic Canc... | 18 Years - | Northwestern University | ||
| Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer | NCT00867321 | Liver Cancer | bevacizumab sorafenib tosyl... | 18 Years - 120 Years | Alliance for Clinical Trials in Oncology | |
| Sorafenib Tosylate in Treating Patients With Liver Cancer Who Have Undergone a Liver Transplant | NCT00844168 | Adult Primary H... Advanced Adult ... Localized Resec... Localized Unres... Recurrent Adult... | sorafenib tosyl... laboratory biom... | 18 Years - | University of Washington | |
| Erlotinib in Treating Patients With Unresectable Liver, Bile Duct, or Gallbladder Cancer | NCT00033462 | Adult Primary C... Adult Primary H... Advanced Adult ... Cholangiocarcin... Cholangiocarcin... Localized Unres... Recurrent Adult... Recurrent Extra... Recurrent Gallb... Unresectable Ex... Unresectable Ga... | erlotinib hydro... laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Cediranib Maleate in Treating Patients With Locally Advanced or Metastatic Liver Cancer | NCT00238394 | Adult Primary H... Advanced Adult ... Localized Unres... | cediranib malea... laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Sunitinib in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery | NCT00514228 | Liver Cancer | sunitinib malat... | 18 Years - | Swiss Group for Clinical Cancer Research | |
| 3-Tesla MRI Response to TACE in HCC (Liver Cancer) | NCT02057874 | Adult Primary H... Advanced Adult ... Localized Resec... Localized Unres... Stage A Adult P... Stage B Adult P... | 3 Tesla Magneti... Magnevist® (Int... | 18 Years - | Vanderbilt-Ingram Cancer Center | |
| PET-CT in Determining the Radioembolization Dose Delivered to Patients With Liver Metastasis, Primary Liver Cancer, or Biliary Cancer | NCT02088775 | Adult Primary H... Advanced Adult ... Metastatic Extr... Recurrent Adult... Recurrent Extra... Stage D Adult P... Unspecified Adu... | PET scan CT Scan hepatic artery ... | 18 Years - | Fox Chase Cancer Center | |
| Epirubicin and Celecoxib in Treating Patients With Hepatocellular Carcinoma | NCT00057980 | Liver Cancer | celecoxib epirubicin hydr... | 18 Years - | Northwestern University | |
| AZD2171 in Treating Patients With Locally Advanced Unresectable or Metastatic Liver Cancer | NCT00427973 | Adult Primary H... Advanced Adult ... Localized Unres... Recurrent Adult... | cediranib malea... laboratory biom... computed tomogr... dynamic contras... pharmacological... | 18 Years - | National Cancer Institute (NCI) | |
| Combination Chemotherapy Plus Interferon Alfa Followed by Filgrastim in Treating Patients With Gastrointestinal Tract Cancer | NCT00019474 | Extrahepatic Bi... Gastric Cancer Gastrointestina... Liver Cancer Pancreatic Canc... Small Intestine... | filgrastim recombinant int... fluorouracil hydroxyurea | 18 Years - 120 Years | Montefiore Medical Center | |
| Chemoembolization and Bevacizumab in Treating Patients With Liver Cancer That Cannot Be Removed With Surgery | NCT00049322 | Liver Cancer | bevacizumab | 18 Years - | Jonsson Comprehensive Cancer Center | |
| Octreotide in Treating Patients With Locally Advanced or Metastatic Liver Cancer | NCT00257426 | Liver Cancer | octreotide acet... | 18 Years - | UNC Lineberger Comprehensive Cancer Center | |
| Yttrium Y 90 Radiolabeled Glass Beads in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery | NCT00589030 | Liver Cancer | brachytherapy yttrium Y 90 gl... | 18 Years - | City of Hope Medical Center | |
| Hepatic Arterial Chemoembolization With Cisplatin or Internal Radiation Therapy in Treating Patients With Advanced Liver Cancer That Cannot Be Removed By Surgery | NCT00109954 | Liver Cancer | cisplatin brachytherapy yttrium Y 90 gl... | 18 Years - 120 Years | University of Pittsburgh | |
| Liposomal Doxorubicin in Treating Patients With Liver or Bile Duct Cancer | NCT00003296 | Extrahepatic Bi... Gallbladder Can... Liver Cancer | filgrastim pegylated lipos... | 18 Years - | National Cancer Institute (NCI) | |
| Combination Chemotherapy and Thalidomide in Treating Younger Patients Undergoing Surgery For Newly Diagnosed Liver Cancer | NCT00276705 | Liver Cancer | cisplatin cyclophosphamid... doxorubicin hyd... thalidomide adjuvant therap... conventional su... neoadjuvant the... | - 29 Years | National Cancer Institute (NCI) | |
| Stereotactic Radiation Therapy and Sorafenib in the Treatment of Hepatocellular Carcinoma | NCT01005875 | Hepatocellular ... Liver Cancer | Sorafenib Stereotactic Bo... | 19 Years - | University of Alabama at Birmingham | |
| Sorafenib Tosylate and Hypoxia-Activated Prodrug TH-302 in Treating Patients With Advanced Kidney Cancer or Liver Cancer That Cannot Be Removed By Surgery | NCT01497444 | Kidney Cancer Liver Cancer | hypoxia-activat... sorafenib tosyl... | 18 Years - | Alliance for Clinical Trials in Oncology | |
| Temsirolimus in Treating Patients With Advanced Liver Cancer and Cirrhosis | NCT01079767 | Liver Cancer | temsirolimus | 18 Years - | Federation Francophone de Cancerologie Digestive | |
| Vaccine Therapy Plus Biological Therapy in Treating Adults With Metastatic Solid Tumors | NCT00019331 | Colorectal Canc... Endometrial Can... Head and Neck C... Liver Cancer Lung Cancer Melanoma (Skin) Pancreatic Canc... Testicular Germ... Unspecified Adu... | aldesleukin ras peptide can... sargramostim DetoxPC | 18 Years - | National Cancer Institute (NCI) | |
| Yttrium Y 90 Radiolabeled Glass Beads in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery | NCT00589030 | Liver Cancer | brachytherapy yttrium Y 90 gl... | 18 Years - | City of Hope Medical Center | |
| Chemoembolization and Bevacizumab in Treating Patients With Liver Cancer That Cannot Be Removed With Surgery | NCT00049322 | Liver Cancer | bevacizumab | 18 Years - | Jonsson Comprehensive Cancer Center | |
| Chemoembolization Using Doxorubicin in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery | NCT00293397 | Liver Cancer | Drug-eluting be... | 18 Years - 120 Years | Yale University | |
| Sunitinib and Chemoembolization in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery | NCT00524316 | Liver Cancer | doxorubicin hyd... sunitinib malat... laboratory biom... hepatic artery ... quality-of-life... | 18 Years - 120 Years | Roswell Park Cancer Institute | |
| Dolastatin 10 in Treating Patients With Metastatic Or Recurrent Liver, Bile Duct, or Gallbladder Cancer | NCT00003557 | Extrahepatic Bi... Gallbladder Can... Liver Cancer | dolastatin 10 | 18 Years - | University of Chicago | |
| Combination Chemotherapy and Interferon Alfa-2b in Treating Patients With Nonmetastatic Liver Cancer That Cannot Be Removed by Surgery | NCT00471484 | Liver Cancer | recombinant int... doxorubicin hyd... fluorouracil oxaliplatin diagnostic labo... immunoenzyme te... immunohistochem... adjuvant therap... biopsy neoadjuvant the... therapeutic con... | 16 Years - 75 Years | National Cancer Institute (NCI) | |
| Sunitinib and Chemoembolization in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery | NCT00524316 | Liver Cancer | doxorubicin hyd... sunitinib malat... laboratory biom... hepatic artery ... quality-of-life... | 18 Years - 120 Years | Roswell Park Cancer Institute | |
| Sorafenib Tosylate in Treating Patients With Liver Cancer That Can Be Removed by Surgery | NCT01182272 | Liver Cancer | sorafenib tosyl... laboratory biom... neoadjuvant the... therapeutic con... | 18 Years - | National Cancer Institute (NCI) | |
| Lapatinib in Treating Patients With Locally Advanced or Metastatic Biliary Tract or Liver Cancer That Cannot Be Removed By Surgery | NCT00101036 | Adult Primary H... Advanced Adult ... Localized Unres... Recurrent Adult... Recurrent Extra... Recurrent Gallb... Unresectable Ex... Unresectable Ga... | lapatinib ditos... laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Oxaliplatin, Capecitabine, and Cetuximab in Treating Patients With Advanced Liver Cancer | NCT00483405 | Liver Cancer | cetuximab capecitabine oxaliplatin | 18 Years - 120 Years | UNC Lineberger Comprehensive Cancer Center | |
| Transarterial Chemoembolization Using Doxorubicin Beads With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery | NCT01324076 | Liver Cancer | doxorubicin-elu... sorafenib tosyl... laboratory biom... pharmacogenomic... pharmacological... quality-of-life... | 18 Years - | National Cancer Institute (NCI) |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
